key: cord-0995123-yndbq4j7
authors: Hopkins, Claire; Vaira, Luigi Angelo; De Riu, Giacomo
title: Self‐reported olfactory loss in COVID‐19: is it really a favorable prognostic factor?
date: 2020-05-12
journal: Int Forum Allergy Rhinol
DOI: 10.1002/alr.22608
sha: a3827ec032d331c6e44a4affc96adcee7618f97d
doc_id: 995123
cord_uid: yndbq4j7

nan

Sassari, Italy.

Keywords: Covid-19; ageusia; anosmia; smell disorders; taste disorders; coronavirus; SARS-CoV-2

To the Editor:

We read with great interest the study by Yan et al (1) recently published in IFAR. Based on data collected from the medical records of 169 coronavirus disease-19 (COVID-19) patients, the authors reported that the presence of chemosensitive disorders is significantly related to the development of milder forms of COVID-19. Moreover, the authors suggest that these findings may allow the lay public and healthcare workers to stratify patients at risk of severe disease and in need of admission, while conserving health care resources by identifying those suitable for outpatient care. The article had significant resonance and was reported widely by the American media. The suggestion that the presence of chemosensitive disorders can reassure patients as predicting a milder clinical course certainly has a strong appeal to a lay public deeply concerned about the current pandemic. However, we think that in times of great uncertainty; caution is needed before disseminating information that can influence people's healthcare seeking behaviour.

Chemosensitive disorders appear to be frequent and often early symptoms of COVID-19, but their prognostic value has not yet been clarified. Certainly, the prevalence of self-reported loss of sense of smell or taste varies between studies of mild to moderate or severe disease (2) .

However, published studies are mostly anamnestic; as Yan and co-authors suggest, these may be prone to recall bias, with under-reporting of loss of smell or taste in the presence of severe respiratory disease. Emerging studies based on objective evaluation of patients in fact suggest that there is no significant correlation between the prevalence of chemosensitive disorders and COVID-19 severity, supporting this proposal (3) (4) (5) . Furthermore, in our recent analysis of a series of 345 cases, patients with a duration of chemosensitive symptoms longer than 7 days had a 2.33 greater risk of developing severe symptoms (5) . We have also demonstrated how anamnestic data collection underestimates the frequency of chemosensitive disorders detected in psychophysical tests, particularly in patients with more serious presentation. It seems likely that these patients have the same prevalence of chemosensitive dysfunction as patients with mild and moderate forms but neglect these symptoms whilst suffering with and receiving supportive treatment for severe respiratory disease.

On the basis of the objective data now emerging in the literature we think that, at present, it is not possible to affirm that olfactory and gustatory disturbances predict a milder course of 

Self-reported olfactory loss associates with outpatient clinical course in Covid-19. Int Forum Allergy Rhinol

Self-reported alteration of sense of smell or taste in patients with SARS-CoV-2 infection: A systematic review and meta-analysis on 3563 patients

Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases

Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol

Olfactory and gustatory function impairment in COVID-19 patients: An Italian objective multicenter-study. Head Neck. Accepted for publication